Literature DB >> 18437095

Sivelestat relaxes porcine coronary artery via inhibition of Ca2+ sensitization induced by a receptor agonist.

Yoshinori Maeda1, Shinji Mitsumizo, Fengling Guo, Hiroko Kishi, Sayaka Matsuo, Sei Kobayashi, Mikio Nakashima.   

Abstract

Sivelestat sodium hydrate (sivelestat) is a novel synthetic drug and specific inhibitor of neutrophil elastase that has been approved in Japan as a treatment for acute lung injury associated with systemic inflammatory response syndrome. There are no reports on the effects of sivelestat on the contractile regulation of vascular smooth muscle. The purpose of the present study was to assess the effects of sivelestat on porcine coronary artery. Sivelestat induced concentration-dependent (3 x 10 to 3 x 10 M) vasorelaxation in U46619 (100 nM)-precontracted porcine coronary artery with or without endothelium. Simultaneous measurements of tension and the cytosolic Ca concentration ([Ca]i) revealed that sivelestat shifted the [Ca]i-tension curve to the right and downward during stimulation with 118 mM K and 100 nM U46619. In beta-escin-permeabilized arterial strips, sivelestat abolished GTP plus U46619-induced contractions at constant [Ca]i, whereas it had no effect on Ca-induced contractions. Thus, sivelestat relaxes porcine coronary artery smooth muscle via the selective inhibition of Ca sensitization induced by a receptor agonist, without affecting Ca-induced contraction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18437095     DOI: 10.1097/FJC.0b013e31816b8c9a

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  2 in total

1.  Sivelestat relaxes vascular smooth muscle contraction in human gastric arteries.

Authors:  Hiroko Amemori; Yoshinori Maeda; Arisu Torikai; Mikio Nakashima
Journal:  J Physiol Biochem       Date:  2011-07-14       Impact factor: 4.158

2.  Sivelestat attenuates myocardial reperfusion injury during brief low flow postischemic infusion.

Authors:  Sverre E Aune; Steve T Yeh; Periannan Kuppusamy; M Lakshmi Kuppusamy; Mahmood Khan; Mark G Angelos
Journal:  Oxid Med Cell Longev       Date:  2013-05-22       Impact factor: 6.543

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.